Fig. 3
Administration of iMSCACVR2B-Fc reduced primary HO in a mouse model of FOP. A Schematic view of the experiments. CTX was injected on day 7. Cells (1.5 × 106) were administrated on days 8, 13, 18, and 23. B Body weight monitoring. C Representative X-ray and μCT images of each group. Arrowheads indicate HO. Scale bar, 10 mm. D Average of HO volume on day 28. E Bone mineral content (BMC) of HO sites. F Endurance tests were conducted using a rodent treadmill. G The exercise capacities were analyzed using the rotarod test. H, I Serum Fc fragment and Activin-A levels were detected by ELISA. Results represent the mean ± SEM. *, P < 0.05 by one-way ANOVA with Tukey’s multiple comparison test